AN2 Therapeutics公司公布,其候选药物AN2-502998的一期临床研究取得了积极结果。数据显示,该药物展现出良好的安全性特征,并且在试验中未观察到剂量限制性毒性。这一进展为后续的临床开发计划奠定了重要基础。
AN2 Therapeutics公司公布,其候选药物AN2-502998的一期临床研究取得了积极结果。数据显示,该药物展现出良好的安全性特征,并且在试验中未观察到剂量限制性毒性。这一进展为后续的临床开发计划奠定了重要基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.